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Objective. The mechanistic target of rapamycin (mTOR) has become a therapeutic target in systemic lupus erythematosus (SLE). In T cells, mTOR plays a central role in lineage specification, including development of regulatory cells (Treg cells). This study sought to investigate whether mTOR is activated within Treg cells and whether this contributes to the depletion and dysfunction of Treg cells in patients with SLE.
Methods. Activities of mTOR complexes 1 (mTORC1) and 2 (mTORC2) were examined by quantifying phosphorylation of translation initiation factor 4E-binding protein 1, S6 kinase, and Akt in SLE patients relative to age-and sex-matched female healthy control subjects. Polarization of Treg cells from naive CD4+ T cells was assessed in the presence of interleukin-6 (IL-6), IL-17, and IL-21. The suppressor function of sorted CD4+CD25+ Treg cells was measured by determining their impact on the proliferation of autologous CD4+CD25À responder T cells. Treg cell expression of FoxP3, GATA-3, and CTLA-4 was monitored by flow cytometry. Autophagy was assessed using immunoblotting of light chain 3 lipidation. The effect of mTOR blockade was evaluated by testing the impact of rapamycin treatment on Treg cell function.
Results. SLE Treg cells exhibited increased activities of mTORC1 and mTORC2, whereas autophagy, the expression of GATA-3 and CTLA-4, and the suppressor function of Treg cells were diminished. IL-21, but not IL-6 or IL-17, blocked the development of Treg cells. IL-21 stimulated mTORC1 and mTORC2, and it abrogated the autophagy, differentiation, and function of Treg cells. Moreover, IL-21 constrained the expression of GATA-3 and CTLA-4 selectively in Treg cells. In turn, blockade of mTORC1 by 3-day rapamycin treatment enhanced transforming growth factor b production, while dual blockade of mTORC1 and mTORC2 by 4-week rapamycin treatment induced autophagy, restored the expression of GATA-3 and CTLA-4, and corrected Treg cell function.
Conclusion. IL-21-driven mTOR activation is a pharmacologically targetable checkpoint of the deficient autophagy that underlies Treg cell dysfunction in SLE.
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology that is characterized by the dysregulated activation of T and B cells and the production of antinuclear antibodies (1) . SLE primarily affects female subjects of childbearing age, and the frequency of mortality in patients with SLE still approaches 10% within 5 years of disease onset (2) . There is an unmet medical need in those with SLE, as current treatments are only partially effective and have significant side effects. However, the development of new and efficacious treatments requires a better understanding of pathogenesis. In this regard, a growing body of evidence points to the depletion of Treg cells as an important mediator of disease (3) (4) (5) (6) . Although the suppressive function of Treg cells is diminished in patients with active SLE (6, 7) , the underlying mechanisms remain unclear.
The mechanistic target of rapamycin (mTOR) is an evolutionally conserved serine/threonine kinase whose primary function is to translate a variety of environmental cues to signals that dictate cell growth, proliferation, and differentiation (8) . Moreover, this kinase has emerged as a central regulator of T cell lineage specification (9) . In particular, constitutively active mTOR and Akt kinase abrogate the differentiation of Treg cells (10) . Genetic ablations of Rheb (Ras homolog enriched in brain) and Rictor (rapamycin-insensitive companion of mTOR) in mice indicate that dual blockade of mTOR complexes 1 (mTORC1) and 2 (mTORC2) are required for the initiation of Treg cell differentiation (9) . Activation of mTOR also plays a central role in T cell dysfunction in SLE (11) , as has been supported by several independent lines of evidence: 1) mTOR activity is increased in the T cells of SLE patients (12) and mice with SLE (13); 2) mTOR controls T cell specification during cell development (9, 14) and controls the skewing of T cells in SLE (15,16); 3) administration of rapamycin improves the clinical outcome in mouse lupus models (13, 17) and in patients with SLE (15,18); 4) rapamycin blocks the production of antiphospholipid antibodies in lupus-prone mice (19) and enhances renal allograft survival in patients with antiphospholipid antibodies (20) , an antibody specificity that represents a diagnostic criterion and source of comorbidity in SLE. However, several important questions remain to be answered: 1) Is mTOR itself activated within Treg cells? 2) Which proinflammatory cues stimulate mTOR within Treg cells? 3) How does mTOR control Treg cell dysfunction in patients with SLE?
Among the proinflammatory cytokines, interleukin-6 (IL-6), IL-17, and IL-21 have attracted growing interest as factors in the pathogenesis of lupus (21) (22) (23) (24) . These cytokines shift the fate of Tcells away from Treg cell development toward differentiation into inflammatory T cells, in a STAT3-dependent manner (25, 26) . However, it is not known whether these cytokines directly restrict human Treg cell development via analogous molecular mechanisms in the setting of SLE.
In addition to the upstream regulators, much remains to be clarified about the signal transduction machineries that control cellular function downstream of mTOR. In this regard, mTOR has been recognized as a suppressor of autophagy, with its primary function appearing to be the regulation of Treg cell lineage stability and function (27) . However, autophagy is enhanced in lupus T cells (28, 29) and B cells (30) . Paradoxically, further enhancement of autophagy via mTOR blockade has therapeutic efficacy both in mice (13, 17) and in patients with SLE (15, 18) .
Treg cells exploit multiple distinct mechanisms in their suppression of effector cell function. They constitutively express FoxP3, which directly controls the expression of CTLA-4 (31). GATA-3 is a transcription factor that mediates the expression of FoxP3 (32) , and it is also essential for Treg cell development and function (33) . Moreover, transforming growth factor b (TGFb) production is indispensable for the differentiation of peripheral Treg cells (34) , and it is sensitive to the suppression of autophagy in other cell types (1, 2, 35) . However, the relationship of TGFb production to mTOR activation and autophagy in Treg cells in general, or in SLE specifically, is presently unknown.
Therefore, in the current study, we examined the state of mTOR activation and its role in the dysfunction of Treg cells, given the clinical efficacy of mTOR blockade previously observed in SLE patients (15, 18, 36) . In this study, we show that Treg cells in patients with SLE exhibit increased activities of mTORC1 and mTORC2 and diminished autophagy and suppressor function, all of which can be effectively restored by treatment with rapamycin.
PATIENTS AND METHODS
Human subjects. In total, 39 patients with SLE fulfilling the American College of Rheumatology diagnostic criteria (37) were studied. In each experiment, peripheral blood was obtained from SLE patients (all female; mean AE SD age 42.4 AE 1.7 years) and from healthy control subjects who were matched to the patients, at the time of blood donation, by age (within 10 years), sex, and ethnic background. The mean AE SD age of the 37 healthy control subjects was 40.6 AE 2.1 years. All blood samples were processed in parallel. The demographics and clinical characteristics of the study subjects are summarized in Supplementary Expansion of Treg cells. CD4+CD25+ Treg cells from SLE patients were cultured for 4 weeks in the presence of plate-bound anti-CD3, soluble anti-CD28, and IL-2, with or without the addition of rapamycin. After 4 weeks of expansion, the Treg cells were used in suppression assays, as described above.
Immunoblotting. In lysates of naive CD4+ T cells cultured under Treg cell-polarizing conditions in the presence or absence of IL-21 or rapamycin, or SLE Treg cells expanded in vitro in the presence or absence of rapamycin, the phosphorylation of STAT3, Akt, S6 kinase, and translation initiation factor 4E-binding protein 1 (4E-BP1), as well as the expression of FoxP3 and light chain 3 (LC3), were determined by immunoblotting (more details on the immunoblotting methods and reagents used are provided in Supplementary Methods; http://onlinelibrary. wiley.com/doi/10.1002/art.40380/abstract).
Cytokine assays. Secretion of cytokines was determined using a Luminex assay (Affymetrix eBioscience) in culture supernatants of CD3+ T cells simulated in vitro for 3 days or CD4+CD25+ Treg cells expanded in vitro for 4 weeks, in the presence or absence of rapamycin (as described in Supplementary Methods).
Statistical analysis. Data are presented as the mean AE SEM, unless stated otherwise. Statistical analyses were performed with the Student's t-test, using GraphPad software. Twotailed P values less than 0.05 were considered significant.
RESULTS
Inhibition of human Treg cell differentiation and function by IL-21. To identify proinflammatory cytokines that may antagonize Treg cell differentiation in SLE, we examined the impact of IL-6, IL-17, and IL-21. These cytokines are known to suppress Treg cell development in mice (25, 26, 38) , whereas their effect on Treg cell differentiation from uncommitted CD4+ T cells has not been clarified in human subjects. Therefore, naive CD4+ T cells were isolated from the peripheral blood of SLE patients and matched healthy control subjects, and the cells were Results are the mean AE SEM. * = P < 0.05; ** = P < 0.01; **** = P < 0.0001, by paired 2-tailed t-test. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40380/abstract. concentrations of 1 ng/ml, 10 ng/ml, or 100 ng/ml. The concentration of 10 ng/ml was used for subsequent studies, because 10 ng/ml of IL-21 suppressed Treg cell differentiation more efficiently than 1 ng/ml, whereas there was no difference between 10 ng/ml and 100 ng/ml with regard to the impact of each concentration on Treg cell differentiation.
We next examined the effects of IL-21 on the suppressor function of Treg cells. CFSE-stained CD4+CD25À responder T cells from SLE patients and healthy controls were stimulated for 5 days with plate-bound anti-CD3 and irradiated PBMCs in the presence or absence of equal numbers of autologous CD4+CD25+ Treg cells and IL-21. The suppressive function of SLE Treg cells was diminished, and this was further inhibited by IL-21 ( Figure 1B) . IL-21 did not enhance the proliferation of responder T cells ( Figure 1B ), suggesting that these effects were mediated by blockade of Treg cell function.
Activation of mTORC1 and mTORC2 and suppression of autophagy by IL-21 during Treg cell differentiation. In mice, both IL-6 and IL-21 inhibit Treg cell differentiation in a STAT3-dependent manner (25, 26) . In contrast, in human subjects, we found that IL-21, but not IL-6, blocked Treg cell differentiation ( Figure 1A and Supplementary Figure  1A [http://onlinelibrary.wiley.com/doi/10.1002/art.40380/ abstract]). These observations prompted us to investigate whether IL-21 exploits STAT3-independent mechanisms to dampen human Treg cell differentiation. To delineate the mechanisms by which IL-21 inhibits Treg cell differentiation, we used immunoblotting to quantify the phosphorylation of STAT3 at tyrosine 705 (pSTAT3 Y705 ) in lysates of naive CD4+ T cells cultured under Treg cell-polarizing conditions. We found that pSTAT3 was up-regulated in SLE T cells, and this was further enhanced by IL-21 ( Figure 2A) . Furthermore, the activities of mTORC1 and mTORC2 were increased in SLE Treg cells, as indicated by the phosphorylation levels of 4E-BP1 and Akt kinase, respectively, and both were further enhanced by the addition of IL-21 ( Figure 2B ). IL-21 did not induce the phosphorylation of S6 kinase (results not shown). Unlike IL-21, IL-6 did not activate mTORC1 or mTORC2, although it phosphorylated STAT3 to a level The signal intensity of p4E-BP1 and pAkt was normalized to that of actin, after which expression was determined relative to that in untreated healthy control samples. Right, Cumulative data show p4E-BP1 expression in 7 samples per group, pAkt expression in 5 samples per group, and the LC3-II: LC3-I ratio in 9 samples per group. Results are the mean AE SEM. * = P < 0.05; ** = P < 0.01, by paired 2-tailed t-test. In accordance with the notion that mTORC1 has a controlling role in autophagy, the lipidation of LC3, i.e., transition of LC3-I to LC3-II, a key regulatory checkpoint of autophagosome formation, was examined by Western blotting. In healthy control subjects, autophagy was prominently increased in Treg cells as compared to effector T and memory CD4+ T cells (results in Supplementary  Figure 2A , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40380/ abstract). Such a distinction was blunted in SLE patients, i.e., autophagy was markedly diminished in Treg cells from SLE patients relative to those from healthy controls (Figure 2B and Supplementary Figure 2A) . In SLE patients, autophagy was enhanced in effector T cells, whereas it was suppressed in memory T cells (results in Supplementary  Figure 2A) .
In healthy control subjects, IL-21 suppressed autophagy in Treg cells ( Figure 2B ) but enhanced autophagy in effector T cells (results in Supplementary Figure  2B [http://onlinelibrary.wiley.com/doi/10.1002/art.40380/ abstract]). However, in patients with SLE, IL-21 failed to further increase the autophagy of effector T cells that had already been enhanced at baseline (results in Supplementary Figures 2A and B) . Moreover, IL-21 inhibited autophagy in memory Tcells from healthy control subjects (results in Supplementary Figure 2C [http://onlinelibrary. wiley.com/doi/10.1002/art.40380/abstract]), which may account for the diminished autophagy of these cells in SLE patients. Importantly, IL-21 further suppressed autophagy in SLE Treg cells that were already exhibiting such a defect at baseline ( Figure 2B ). These findings Results are the mean AE SEM. * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001, by paired 2-tailed t-test. See Figure 1 for other definitions. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40380/abstract.
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identify IL-21-induced mTOR activation and suppression of autophagy as mechanisms that can compromise Treg cell development in SLE. Deficiency of GATA-3 and CTLA-4 in SLE Treg cells. We next sought to evaluate the intrinsic suppressive machineries of Treg cells in SLE patients, since such mechanisms were previously found to be operational in mouse Treg cells (39) . To this end, we quantified intracellular expression of GATA-3 and surface CTLA-4 in freshly isolated Treg cells from SLE patients and healthy controls. Although GATA-3 was overexpressed in the majority of T cell subsets, it was down-regulated rather selectively in Treg cells from SLE patients ( Figure 3A) . Likewise, CTLA-4 expression was diminished in freshly isolated CD4+CD25+FoxP3+ cells from SLE patients ( Figure 4A ). These findings suggest that deficiency of GATA-3 and CTLA-4 may contribute to the functional defects in SLE Treg cells.
Role of IL-21-driven down-regulation of GATA-3 and CTLA-4 in the developmental and functional defects of SLE Treg cells. Since IL-21 inhibited the development and function of Treg cells, its effects on the expression of GATA-3 and CTLA-4 were examined in naive CD4+ Tcells cultured under Treg cell-polarizing conditions. IL-21 effectively blocked GATA-3 expression in CD4+CD25+FoxP3+ Treg cells from healthy controls (P = 0.0075) as well as from patients with SLE (P = 8. Similar to its effects on GATA-3 expression (Figure 3B) , IL-21 suppressed the expression of CTLA-4 selectively and most markedly in FoxP3+ cells ( Figure 4B ). Accordingly, among CFSEÀ cells, the FoxP3+CTLA-4+ T Figure 5 . Dual blockade of mechanistic target of rapamycin complexes 1 and 2 restores autophagy in SLE Treg cells. CD4+CD25+ Treg cells from 4 SLE patients and 1 healthy control were cultured for 4 weeks in the presence of plate-bound anti-CD3, soluble anti-CD28, and interleukin-2 (100 IU/ ml; omitted in the first week of culture), with or without the addition of rapamycin (Rapa) (100 nM). The culture medium was changed every week. Expression of phosphorylated translation initiation factor 4E-binding protein 1 at threonine 37 and 46 (p4E-BP1), phosphorylated S6 kinase at threonine 389 (pS6K1), phosphorylated Akt at serine 473 (pAkt), total Akt, and light chain 3 (LC3) in SLE Treg cells was determined by immunoblotting. A, Left, Representative immunoblots show staining of p4E-BP1 and pS6K1 expression in the presence or absence of rapamycin. The signal intensity was normalized to that of actin, after which expression was determined relative to that in untreated samples. Right, Cumulative data show the expression of p4E-BP1 in 4 SLE samples per group. B, Left, Representative immunoblots show staining of pAkt and Akt in the presence or absence of rapamycin. Right, Cumulative data show the expression of pAkt in 3 SLE samples per group. The signal intensity of pAkt was normalized to that of actin (left panel) or normalized to that of Akt (right panel), after which expression was determined relative to that in untreated samples. C, Left, Representative immunoblots show staining of LC3 expression in cells from 2 patients with SLE (SLE 1 and SLE 2) and a healthy control subject, in the presence or absence of rapamycin. Right, Cumulative data show the LC3-II:LC3-I ratio in 4 SLE samples per group. The signal intensity of LC3-I was normalized to that of actin. Cumulative data show the expression of LC3-I in samples from 4 SLE patients and 1 healthy control relative to that in non-rapamycin-treated samples. Results are the mean AE SEM. * = P < 0.05; ** = P < 0.01, by paired 2-tailed t-test. See Figure 1 for other definitions. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40380/abstract. cell population was reduced from a mean AE SEM 16.8 AE 2.2% to 6.2 AE 0.6% in healthy control subjects (P = 0.00058) and from 24.9 AE 4.6% to 7.4 AE 1.2% in SLE patients (P = 0.0014) ( Figure 4B ). In contrast, IL-21 upregulated the expression of CD28 in CFSE+ responder T cells ( Figure 4C ). Since the opposing effects of CTLA-4 and CD28 on the activation state of T cells have been documented previously in studies showing fatal autoimmunity and excessive CD28 signaling in CTLA-4-deficent mice (40) , this finding supports the notion that IL-21-driven down-regulation of CTLA-4 contributes to the loss of Treg cell suppressor activity in SLE.
In contrast to the effects of IL-21, IL-2 promotes FoxP3 expression and Treg cell development (41) . In this regard, we noted that IL-2 up-regulated the expression of GATA-3, CTLA-4, and FoxP3 in SLE Treg cells (results in Supplementary Figure 4 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40380/abstract), and adenovirus-mediated overexpression of GATA-3 restored FoxP3 expression in SLE Treg cells (results not shown). These findings suggest that IL-21 and IL-2 regulate human Treg cell development and function in a reciprocal manner, by modulating the levels of GATA-3 and CTLA-4.
Restoration of SLE Treg cell function by dual blockade of mTORC1 and mTORC2 via induction of autophagy and corrected expression of GATA-3 and CTLA-4. To determine whether the depletion and dysfunction of Treg cells in patients with SLE could be attributed to mTOR activation, we examined mTOR activity and autophagy in SLE Treg cells that had been expanded in vitro for 4 weeks in the presence or absence of rapamycin. Treatment of SLE Treg cells with rapamycin blocked the phosphorylation of the mTORC1 substrate 4E-BP1 ( Figure 5A ) and the phosphorylation of the mTORC2 substrate Akt (Figure 5B) . Furthermore, blockade of mTOR induced autophagy in the Treg cells, as evidenced by the increased ratio of LC3-II relative to LC3-I as well as the reduced expression of LC3-I in the presence of rapamycin ( Figure 5C ).
We next assessed the effects of mTOR blockade on the expression of GATA-3, expression of CTLA-4, and Treg cell function. Importantly, 4-week rapamycin treatment expanded the proportion of CD4+CD25+FoxP3+ Treg cells in SLE patients by 3.3-fold (P = 0.03) (Figure 6A) , restored SLE Treg cell expression of GATA-3 ( Figure 6B ) and CTLA-4 ( Figure 6C) , and recovered the suppressor function of Treg cells ( Figure 6D ). When naive CD4+ T cells were cultured under Treg cell-polarizing conditions for only 3 days, the addition of rapamycin did not expand Treg cells, and this lack of effect was attributed to the fact that rapamycin blocked the activity of mTORC1 but not mTORC2 (see Supplementary   Figures 5A and B , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40380/abstract). Treg cells expanded in vitro for 4 weeks did not secrete meaningful amounts of IL-21 (results not shown). However, 3-day rapamycin treatment suppressed the production of proinflammatory cytokines, including the production of IL-21, and also restored the CD3+ T cell secretion of TGFb which had been diminished in patients with SLE (results in Supplementary Figure 6A, 
DISCUSSION
IL-21 has emerged as a proinflammatory cytokine in SLE (24, 42) . The present study reveals that IL-21 plays a role in the blockade of Treg cell differentiation and function through the activation of mTORC1 and mTORC2. In mice, IL-6, IL-17, and IL-21 inhibit Treg cell differentiation in a STAT3-dependent manner (25, 26, 38) . As shown in the present study, IL-21, but not IL-6, blocked Treg cell differentiation, yet both of these cytokines phosphorylated STAT3 to comparable levels. The discrepancy between the 2 species is intriguing and raises a possibility that IL-21 exploits STAT3-independent mechanisms to abrogate human Treg cell differentiation. Indeed, we showed that IL-21, but not IL-6, elicited the activation of mTORC1 and mTORC2 and suppressed autophagy in naive CD4+ T cells cultured under Treg cell-polarizing conditions, which likely played an important role in curtailing Treg cell development, since mTOR is a robust antagonist of Treg cell differentiation (9) , and Treg cells need autophagy to maintain their lineage commitment and function (27) .
Our previous studies have highlighted mTORC1 activation as an important mechanism that drives expansion of Th17 cells and IL-4-expressing CD4ÀCD8À double-negative T cells in SLE (15, 16) . The present study unveiled a proinflammatory role of mTORC2 in blocking Treg cell development in SLE, which is consistent with the findings in prior studies showing that the activation of mTORC1 and mTORC2 jointly promoted the differentiation of follicular helper T cells (43) . In this regard, it is noteworthy that in our study, secretion of IL-21 by T cells was blocked by rapamycin. These findings suggest that the IL-21?mTOR?IL-21 axis serves as a self-amplifying 434 KATO AND PERL (44), concrete evidence has been lacking. Nevertheless, the mechanism is likely to be indirect, given that IL-21 binds to a cell surface receptor (44) , while mTOR is located in the cytosol, where it can traffic to endosomes or lysosomes (11) . Rapamycin is known to be therapeutic in SLE (15, 18) , by inducing a striking reversal of Treg cell depletion in vivo (15, 16) . Expansion of CD4+CD25+FoxP3+ Treg cells after 4-week rapamycin treatment enabled dual blockade of mTORC1 and mTORC2, which is consistent with earlier studies showing that prolonged rapamycin treatment also suppressed mTORC2 (45) . In addition to its critical role in Treg cell differentiation, mTORC2 blockade is likely to be essential for lineage stabilization and functional maturation of Treg cells. Such maintenance of Treg cell lineage stability and protection against autoimmunity depend on the inactivation of mTORC2 (46) .
Our understanding of the mechanisms by which mTOR activation curtails Treg cell development has been evolving. Interestingly, phosphorylation of 4E-BP1, but not S6 kinase, was sensitive to IL-21 and rapamycin in the current study. In this regard, it is important to note that rapamycin differentially inhibits the phosphorylation of 4E-BP1 and S6 kinase, depending on the cell types (47) . The robust and reciprocal effects of IL-21 and rapamycin on autophagy and phosphorylation of 4E-BP1 indicate that this substrate of mTORC1 controls the transcriptional machinery involved in Treg cell development and function. Without directly implicating autophagy, mTORC1 activation has been shown to induce proteasomal degradation of FoxP3 (48) . In turn, mTORC2 activation phosphorylates Akt, which inhibits FoxP3 expression by inactivating FoxO1 and FoxO3 (49) . Similar to earlier studies in mice (27) , autophagy was increased in Treg cells over effector T cells in healthy control subjects. However, this difference was abrogated in SLE patients, as autophagy was increased in naive and proinflammatory effector CD4+ T cells but profoundly diminished in Treg cells. Such a blockade of autophagy in Treg cells is attributed to activation of the IL-21-mTORC1 axis in SLE.
In addition, our findings pinpoint specific molecular targets downstream of mTOR pathway activation in lupus Treg cells. Meaningful Treg cell suppression was observed only when irradiated PBMCs were used to stimulate responder T cells, but not when responder T cells were stimulated with plate-bound anti-CD3 and soluble anti-CD28, suggesting that Treg cell suppression requires the contribution by APCs in primary human cells (see Supplementary Figure 7 [http://onlinelibrary.wiley.com/ doi/10.1002/art.40380/abstract]). Of note, IL-21-driven down-regulation of CTLA-4 in Treg cells was associated with reciprocal up-regulation of CD28 expression in the responder T cells. These findings are consistent with the notion that CTLA-4-dependent down-regulation of CD80/CD86 on APCs is critical for the suppressor function of Treg cells (39) . In the current study, IL-21 downregulated, whereas IL-2 up-regulated, the expression of GATA-3 and CTLA-4 in Treg cells, suggesting that the opposing effects of these cytokines on Treg cell development are mediated through GATA-3 and CTLA-4. Along these lines, IL-21 inhibited the expression of GATA-3 and CTLA-4 in CD4+CD25+FoxP3+ cells, but not in CD4+CD25+FoxP3À cells. In a reciprocal manner, mTOR blockade restored the diminished expression of GATA-3 and CTLA-4 specifically in FoxP3+ cells, but not in FoxP3À cells, in patients with SLE. These results indicate that mTOR negatively regulates GATA-3 and CTLA-4 in a Treg cell-specific manner, and that IL-21-driven activation of mTORC1 and mTORC2 abrogates Treg cell differentiation and function by suppressing the expression of GATA-3 and CTLA-4.
Furthermore, we found that mTORC1 blockade restored the diminished production of TGFb by SLE T cells. Notably, there is evidence that autophagy induces TGFb expression in other cell types (35) . In turn, TGFb stimulates the expression of FoxP3 (34) , which binds to the promoters of GATA3 and CTLA4 to control their expression (31) . These findings collectively unveil an intriguing paradigm whereby TGFb connects the IL-21-mTOR autophagy axis with the deficient, GATA-3/FoxP3-dependent expression of CTLA-4 in lupus Treg cells (see Supplementary Figure 6B [http:// onlinelibrary.wiley.com/doi/10.1002/art.40380/abstract]).
Most recently, checkpoint inhibitors, such as anti-CTLA-4, have revolutionized cancer immunotherapy, but such treatments often result in unwanted development of autoimmunity (50) . Thus, beyond the unveiling of a direct role of mTOR in Treg cell depletion during the pathogenesis of SLE and the newer therapeutic interventions in SLE (11), the present findings have broad implications with regard to the normal development of Treg cells as well as the autoimmunity induced by treatment with checkpoint inhibitors (51) .
